



First AIA Review of Pharmaceutical Patents

Jun 26, 2014

Reading Time : **1 min**

By: Rubén H. Muñoz

According to Ryan Davis's *Law360* article, "Merck Supplement Patents Nixed in 1st Pharma AIA Reviews," "only about 6 percent of the AIA petitions filed to date have challenged pharmaceutical patents," making this possibly the "first inter partes review involving pharmaceuticalrelated patents."

Gnosis S.P.A. v. South Alabama Medical Science Foundation, IPR201300116, IPR201300118 & IPR201300119 (PTAB June 20, 2014) [Kamholz (opinion); Bonilla; Snedden]; *Gnosis, S.P.A. v. Merck & CIE*, IPR20130017 (PTAB June 20, 2014) [Kamholz (opinion); Bonilla; Snedden].

Categories

Patent Trial & Appeal Board

Inter Partes Review

© 2025 Akin Gump Strauss Hauer & Feld LLP. All rights reserved. Attorney advertising. This document is distributed for informational use only; it does not constitute legal advice and should not be used as such. Prior results do not guarantee a similar outcome. Akin is the practicing name of Akin Gump LLP, a New York limited liability partnership authorized and regulated by the Solicitors Regulation Authority under number 267321. A list of the partners is available for inspection at Eighth Floor, Ten Bishops Square,

London E1 6EG. For more information about Akin Gump LLP, Akin Gump Strauss Hauer & Feld LLP and other associated entities under which the Akin Gump network operates worldwide, please see our Legal Notices page.